Short answer
Rapport Therapeutics, Inc. (RAPP) filed an 8-K current report with the SEC on October 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 1.01 (Entry into a Material Definitive Agreement). $215.7M net equity proceeds, including 11,190,476 shares or pre-funded warrants plus 1,428,571 exercised option shares.
Rapport Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $215.7M net equity proceeds, including 11,190,476 shares or pre-funded warrants plus 1,428,571 exercised option shares
- $166.8M net convertible-note proceeds, adding $172.5M principal at 2.25% interest due December 1, 2032
- Total financing approximately $382.5M, expected to fund operations through 2029 and advance RAP-219 clinical trials
- Convertible notes initially convert at $26.7750 per share, a 27.50% premium to the $21.00 equity offering price
- Additional dilution risk from 1,428,571 PIPE shares and future note conversion, with PIPE resale registration required by December 29, 2026
Item 2.02 · Results of Operations and Financial Condition
- Preliminary cash, equivalents and short-term investments of approximately $395.0 million as of September 30, 2026
- Liquidity disclosure accompanied underwritten offerings, potentially supporting ongoing clinical development and operations
- Estimate covers the three months ended September 30, 2026 and remains subject to material review adjustments
- Final results expected in the Form 10-Q, with no earnings or expense figures disclosed here
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01, indicating a material financial obligation arose through an agreement
- Investors should review Item 1.01 for obligation amount, payment terms, interest rate, maturity and use of proceeds
Item 3.02 · Unregistered Sales of Equity Securities
- PIPE shares sold privately to accredited investors under Section 4(a)(2) exemption
- Shares unregistered, creating resale restrictions and potential future registration needs
- Event implies equity financing and dilution, with transaction terms referenced under Item 1.01
- Investors should review Item 1.01 for proceeds, share count, pricing and use of funds
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Rapport Therapeutics, Inc. 8-K filings
Get the next RAPP 8-K as it lands
Follow RAPP for push alerts, or ask the research agent what this filing means.